AbbVie Inc (ABBV)vsVivos Therapeutics Inc (VVOS)
ABBV
AbbVie Inc
$257.60
-2.16%
HEALTHCARE · Cap: $447.53B
VVOS
Vivos Therapeutics Inc
$0.41
-1.45%
HEALTHCARE · Cap: $5.83M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 320929% more annual revenue ($62.82B vs $19.57M). ABBV leads profitability with a 5.8% profit margin vs -127.7%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
VVOS
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-78.8%
Fair Value
$147.26
Current Price
$257.60
$110.34 premium
Margin of Safety
+24.0%
Fair Value
$2.04
Current Price
$0.41
$1.63 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
Reasonable price relative to book value
Revenue surging 70.5% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -1600.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.42 suggests the stock is reasonably priced for its growth.
Bull Case : VVOS
The strongest argument for VVOS centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 70.5% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 124.8x leaves little room for execution misses.
Bear Case : VVOS
The primary concerns for VVOS are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while VVOS is a hypergrowth play — different risk/reward profiles.
VVOS carries more volatility with a beta of 6.12 — expect wider price swings.
VVOS is growing revenue faster at 70.5% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 31/100) and 12.4% revenue growth. VVOS offers better value entry with a 24.0% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Vivos Therapeutics Inc
HEALTHCARE · MEDICAL DEVICES · USA
Vivos Therapeutics, Inc., a medical technology company, is dedicated to developing and commercializing treatment alternatives for patients with sleep-disordered breathing, such as mild to moderate obstructive sleep apnea (OSA). The company is headquartered in Highlands Ranch, Colorado.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?